Compare SON & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | RYTM |
|---|---|---|
| Founded | 1899 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.8B |
| IPO Year | 2014 | 2017 |
| Metric | SON | RYTM |
|---|---|---|
| Price | $49.98 | $98.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $60.13 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.1M | 543.4K |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 510.30 | 28.34 |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $7,518,753,000.00 | N/A |
| Revenue This Year | $0.10 | $55.34 |
| Revenue Next Year | $1.82 | $86.06 |
| P/E Ratio | $73.49 | ★ N/A |
| Revenue Growth | ★ 41.72 | N/A |
| 52 Week Low | $38.65 | $74.50 |
| 52 Week High | $60.67 | $122.20 |
| Indicator | SON | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 39.36 | 38.60 |
| Support Level | $46.74 | $82.43 |
| Resistance Level | $58.08 | $99.50 |
| Average True Range (ATR) | 1.27 | 3.56 |
| MACD | 0.30 | -0.04 |
| Stochastic Oscillator | 63.87 | 27.70 |
Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.